IVF Treatment Clinical Trial
Official title:
Serum Concentration of HE4, a New Marker for Ovarian Cancer, Changes Little Throughout IVF Stimulation
Human epididymal secretory protein 4 (HE4) is a new biomarker for ovarian cancer. The effect
of IVF stimulation will be evaluated in order to see whether severe hormonal changes in the
gonadotrophin and steroid status affect the serum levels of this marker. Findings will be
compared to serum concentrations of CA-125, which is currently the most often used marker
for ovarian cancer.
The intention is to determine the serum concentration of HE4 and CA-125 in serial samples in
20 women undergoing IVF stimulation. Samples will be taken following GnRH agonist
suppression, 2-3 times during FSH stimulation, at ovum pick up and two weeks following
embryo transfer at the time of the hCG-test. The ovarian follicle count and the serum
estradiol concentrations are recorded throughout the treatment. The serum biomarker HE4 is
expected to ba a stable marker, which does not respond significantly to hormonal
stimulation.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03660813 -
Follicle Size and Oocyte Development
|
N/A | |
| Completed |
NCT01781143 -
Self-operated Endo-vaginal Telemonitoring (SOET), an Economic and Patient-empowered Method for Ovarian Stimulation for In-vitro Fertilization (IVF)
|
N/A | |
| Completed |
NCT00461422 -
Early Follicular Supplementation of Ganirelix in IVF 2004
|
Phase 4 |